Patents Issued in July 25, 2017
  • Processes and intermediates for making a JAK inhibitor
    Patent number: 9714233
    Abstract: This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of Janus kinases (JAK) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: July 25, 2017
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Pingli Liu, Dengjin Wang, Yongzhong Wu, Ganfeng Cao, Michael Xia
  • Carbazole carboxamide compounds
    Patent number: 9714234
    Abstract: Disclosed are compounds of Formula (I); and salts thereof, wherein: Formula (II); Q is: R1 is —C(CH3)2OH, —NHC(=0)C(CH3)3, —N(CH3)2, or —CH2Rd; R2 is CI or —CH3; R3 is H, F, or —CH3; Ra is H or —CH3; Rb is H, F, CI, or —OCH3 Rc is H or F; and Rd is —OH, —OCH3, —NHC(=0)CH3, or fORMULA (III), Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: July 25, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Soo Sung Ko, Douglas G Batt, Myra Beaudoin Bertrand, George Delucca, Charles M. Langevine, Qingjie Liu, Anurag S. Srivastava, Scott Hunter Watterson
  • Quinazoline derivatives, compositions thereof, and use as pharmaceuticals
    Patent number: 9714235
    Abstract: Disclosed herein are protein kinase inhibitors, more particularly novel quinazoline derivatives and pharmaceutical compositions thereof, and method of use thereof.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: July 25, 2017
    Assignee: Shanghai Fochon Pharmaceutical Co., Ltd.
    Inventors: Weibo Wang, Xingdong Zhao, Tongshuang Li, Qiang Tian, Ling Chen, Zuwen Zhou, Zhifu Li, Xianlong Wang, Yue Rong, Lihua Jiang, Yanxin Liu, Jing Sun, Fanxin Zeng
  • Compounds and methods for inhibiting JAK
    Patent number: 9714236
    Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: July 25, 2017
    Assignee: ASTRAZENECA AB
    Inventors: Neil Grimster, Sameer Kawatkar, Jason Grant Kettle, Qibin Su, Melissa Vasbinder, Claudio Edmundo Chuaqui
  • Material for organic electroluminescent device and organic electroluminescent device using same
    Patent number: 9714237
    Abstract: The present invention provides a material for an organic electroluminescence device having a specific structure in which a dibennzofuranyl group or a dibenzothiophenyl group is bonded at an N-position (9-position) of a carbazolyl group and an organic electroluminescence device which is provided with one or more organic thin film layers including a light emitting layer between a cathode and an anode and in which at least one layer of the organic thin film layers described above contains the material for an organic electroluminescence device according to the present invention.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: July 25, 2017
    Assignee: IDEMITSU KOSAN CO., LTD.
    Inventors: Masaki Numata, Hideaki Nagashima
  • Therapeutic agents for ocular hypertension
    Patent number: 9714238
    Abstract: This invention provides well defined 6-alkyl or hydroxyalkyl-1-naphthamide or quinoline compounds for treating glaucoma or ocular hypertension.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: July 25, 2017
    Assignee: ALLERGAN, INC.
    Inventor: David W. Old
  • N-phenyl-lactam derivatives capable of stimulating neurogenesis and their use in the treatment of neurological disorders
    Patent number: 9714239
    Abstract: The present invention relates to compounds of the general formula I wherein Het, R1, R2, W and X are as defined herein. Compounds of formula I are useful for treating neuropsychiatric disorders.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: July 25, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Roland Jakob-Roetne, Juergen Wichmann, Jens-Uwe Peters, Ravi Jagasia
  • Vinyl autotaxin inhibitor compounds
    Patent number: 9714240
    Abstract: Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: July 25, 2017
    Assignee: PHARMAKEA, INC.
    Inventors: John Howard Hutchinson, Timothy Andrew Parr, David Lonergan
  • Cyclopropanamine compound and use thereof
    Patent number: 9714241
    Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: July 25, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shigemitsu Matsumoto, Yasushi Hattori, Masashi Toyofuku, Shinji Morimoto, Takuto Kojima, Tomohiro Kaku, Mitsuhiro Ito
  • Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists
    Patent number: 9714242
    Abstract: The invention relates to novel benzothiophene-, benzofuran-, and indole ureas and to the use thereof for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning, and/or memory.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: July 25, 2017
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Timo Fleβner, Frank-Gerhard Böβ, Christina Erb, Frank-Thorsten Hafner, Katrin Schnizler, Dieter Lang, Joachim Luithle, Marja Van Kampen, Franz-Josef Van Der Staay
  • 4-pyridinonetriazine derivatives as HIV integrase inhibitors
    Patent number: 9714243
    Abstract: The present invention relates to 4-Pyridinonetriazine Derivatives of Formula (I); and pharmaceutically acceptable salts thereof, wherein A, X, Y, R1, R2, R3 and R5 are as defined herein. The present invention also relates to compositions comprising at least one 4-Pyridinonetriazine Derivative, and methods of using the 4-Pyridinonetriazine Derivatives for treating or preventing HIV infection in a subject.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: July 25, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Mark W. Embrey, Thomas H. Graham, Abbas Walji, Sherman T. Waddell, Tao Yu, Yonglian Zhang, Wensheng Liu, Paul J. Coleman, John Wai, Thomas Steele, Christina Di Marco
  • Substituted pyrido[4,3-d]pyrimidines as Wee-1 inhibitors
    Patent number: 9714244
    Abstract: The present invention relates to compounds of formula (I) that are useful as inhibitors of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in the treatment of cancer and methods of treating cancer.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: July 25, 2017
    Assignee: ALMAC DISCOVERY LIMITED
    Inventors: Colin Roderick O'Dowd, James Samuel Shane Rountree, Frank Burkamp, Andrew John Wilkinson
  • Carboline compounds usable in the treatment of neurodegenerative diseases
    Patent number: 9714245
    Abstract: The present invention relates to a compound according to Formula (A) or a pharmaceutically acceptable salt, solvate, clathrate, hydrate or polymorph thereof, and its use.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: July 25, 2017
    Assignees: ALZPROTECT, UNIVERSITE DE LILLE 2 DROIT ET SANTE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Patricia Melnyk, Pascal Carato, Stephane Burlet, Emilie Nguyen, Philippe Verwaerde, Nicolas Sergeant, Cecilia Estrella
  • [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
    Patent number: 9714246
    Abstract: Compounds having a structure of formula (I), including stereoisomers and pharmaceutically acceptable salts and solvates thereof: wherein R1 is as defined herein. Such compounds are inhibitors of the vesicular monoamine transporter 2 (VMAT2) and have utility for treating, for example, hyperkinetic disorders. Also disclosed are compositions containing these compounds in combination with a pharmaceutically acceptable carrier or diluent, as well as methods relating to the use in a subject in need thereof.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: July 25, 2017
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Neil Ashweek, Nicole Harriott
  • Multiple kinase pathway inhibitors
    Patent number: 9714247
    Abstract: Kinase with inhibitory activity against kinases disposed in multiple signaling pathways and their therapeutic uses.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: July 25, 2017
    Assignees: Tolero Pharmaceuticals, Inc., Mannkind Corporation
    Inventors: Qingping Zeng, Mary Faris, Alexis Mollard, Steven L. Warner, Gary A. Flynn
  • Therapeutically active pyrazolo-pyrimidine derivatives
    Patent number: 9714248
    Abstract: A series of pyrazolo[3,4-d]pyrimidine derivatives that are substituted at the 4-position by a diaza monocyclic, bridged bicyclic or spirocyclic moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: July 25, 2017
    Inventors: Daniel James Ford, Richard Jeremy Franklin, Anant Ramrao Ghawalkar, Helen Tracey Horsley, Qiuya Huang, James Thomas Reuberson, Bart Vanderhoydonck
  • Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
    Patent number: 9714249
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the pyrazolo-pyrrolidin-4-one derivatives, and their use as BET inhibitors for the treatment of conditions or diseases such as cancer. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: July 25, 2017
    Assignee: Novartis AG
    Inventors: Jutta Blank, Simona Cotesta, Vito Guagnano, Heinrich Rueeger
  • Crystalline forms of temozolomide and the method for preparing same
    Patent number: 9714250
    Abstract: Provided in the present invention are a new method for preparing the crystalline forms of Temozolomide and three types of crystalline form of Temozolomide by the method. Said method comprises the following steps: a Temozolomide is dissolved into dimethyl sulphoxide, a second organic solvent is added for recrystallization to prepare the crystalline forms of Temozolomide, wherein the second organic solvent is an alcohol, a ketone, a halohydrocarbon or an ester.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: July 25, 2017
    Assignee: Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
    Inventors: Guocheng Wang, Wenzheng Liu, Yuzhe Gao, Hailong Yang, Qingwei Hou, Yu Zhang
  • Imidazotriazine derivatives as modulators of TNF activity
    Patent number: 9714251
    Abstract: A series of substituted imidazo[1,2-b][1,2,4]triazine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: July 25, 2017
    Assignee: UCB Biopharma SPRL
    Inventors: Daniel Christopher Brookings, Julien Alistair Brown, Victoria Elizabeth Jackson, John Robert Porter, Joanna Rachel Quincey
  • Cyclic sulfonamides as sodium channel blockers
    Patent number: 9714252
    Abstract: The present disclosure provides cyclic sulfonamides of Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3a, R3b, and n are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. For example, compounds of the present disclosure are useful for treating pain.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: July 25, 2017
    Assignee: Purdue Pharma L.P.
    Inventor: Mark Andrew Youngman
  • Organic thin film transistor, organic semiconductor thin film, and organic semiconductor material
    Patent number: 9714253
    Abstract: An organic thin film transistor having a semiconductor active layer containing a compound represented by the formula (1) has a high carrier mobility and a small change in the threshold voltage after repeated operation. R1 to R10 represent H or a substituent, provided that at least one of R1 to R4 and R6 to R9 represents a substituent represented by -L-R, L represents a specific divalent linking group, and R represents an alkyl group, an oligooxyethylene group, an oligosiloxane group, or a trialkylsilyl group.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: July 25, 2017
    Assignee: FUJIFILM Corporation
    Inventors: Tetsu Kitamura, Koji Takaku, Wataru Sotoyama, Yuki Hirai, Masaru Kinoshita, Yuuta Shigenoi
  • Anilino podophyllin derivative having antitumor activity, method for preparation thereof, and use thereof
    Patent number: 9714254
    Abstract: The present invention discloses an anilino-substituted podophyllin derivative having antitumor activity, method for preparation thereof, and use thereof. By means of anilino reactions, the present invention introduces 4-chloro-3-methylaniline, 3-fluoro-4-methoxyaniline, 4,4?-diaminodiphenylmethane, o-anisidine, 4-chloro-2-aminoanisole, anthranilonitrile, 2,6-dichloro-4-aminophenol, N,N-dimethylamino meta-aniline, 2-ethyl-5-nitroaniline, 2 2?-diaminodiphenylsulfide, or 2-aminobenzotrifluoride into position 4 of the active C-ring of podophyllotoxin or 4?-demethylepipodophyllotoxin to obtain the aniline-substituted podophyllotoxin derivative shown in formula (V); by means of multi-pathway and multi-target effects on tumor cells, said derivative has significantly increased antitumor activity, and can be prepared as an antineoplastic drug and applied in clinical antitumor therapy.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: July 25, 2017
    Assignee: HUBEI UNIVERSITY OF TECHNOLOGY
    Inventors: Yajie Tang, Yong Yang, Wei Zhao, Hongmei Li
  • Cortistatin analogues and syntheses thereof
    Patent number: 9714255
    Abstract: The present invention relates to analogs of cortistatin A, J, K, and L, having the general formula: and salts thereof, wherein R1, R2, R3, R4, n, and m are as defined herein; processes for preparing such compounds and intermediates thereto; pharmaceutical compositions comprising such compounds; methods for treating a proliferative disease; methods for treating a disease associated with aberrant angiogenesis; methods for inhibiting angiogenesis; and processes for preparing cortistatin A, J, K, and L, and analogs thereof.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: July 25, 2017
    Assignee: President and Fellows of Harvard College
    Inventors: Alec Nathanson Flyer, Hong Myung Lee, Andrew G. Myers, Cristina Montserrat Nieto-Oberhuber, Matthew D. Shair, Chong Si
  • Blue electrochromic compound, preparation method and subassembly thereof
    Patent number: 9714256
    Abstract: One class of blue thiophene electrochromic compounds include 3,4-(2,2-bis(2-oxo-3-phenylpropyl))propylenedioxythiophene, 3,4-(2,2-bis(2-oxo-3-phenylbutyl))propylenedioxythiophene, and 3,4-(2,2-bis(2-oxo-3-phenylamyl))propylenedioxythiophene. The thiophene electrochromic compounds can change color between blue and transparency. The thiophene compounds can be electropolymerized on the surface of the ITO glass to form a film. The film has characteristics of low driving voltage (within ±1V), fast response time, and large transmittance difference between colored-state and bleached-state (up to 77.5%). The thiophene electrochromic compounds can be used in the electrochromic window, rearview mirror, electrochomeric display, and the like.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: July 25, 2017
    Assignees: BOE TECHNOLOGY GROUP CO., LTD., UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA
    Inventors: Chunye Xu, Sai Mi, Jianming Zheng
  • Therapeutic agent for motor disorders
    Patent number: 9714257
    Abstract: Provided are an agent for the treatment and/or prophylaxis of a movement disorder, the agent for the treatment and/or prophylaxis wherein the movement disorder is extrapyramidal syndrome, the agent for the treatment and/or prophylaxis wherein the movement disorder is bradykinesia, gait disturbance, dystonia, dyskinesia or tardive dyskinesia, the agent for the treatment and/or prophylaxis wherein the movement disorder is a side effect of L-DOPA and/or dopamine agonist therapy, and the like, each containing a thiazole derivative represented by the formula (I) wherein R1 represents aryl and the like, and R2 represents pyridyl or the like, or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: July 25, 2017
    Assignee: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Noriaki Uesaka, Takashi Sawada, Tomoyuki Kanda
  • Diaryl macrocycles as modulators of protein kinases
    Patent number: 9714258
    Abstract: The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: July 25, 2017
    Assignee: TP Therapeutics, Inc.
    Inventors: Jingrong Jean Cui, Yishan Li, Evan W. Rogers, Dayong Zhai
  • Compositions and methods for improving glucose uptake
    Patent number: 9714259
    Abstract: A compound includes the structure of general Formula II, pharmaceutically acceptable salts thereof, and/or solvates thereof: wherein R1, R2, R3, are independently selected from the group consisting of null, hydroxy, alkoxy, and halo, or R1 and R2 taken together form a cyclic boronate ester and R3 is null; wherein when four bonds to boron are present, boron bears a formal negative charge and the structure further comprises a countercation that is potassium or sodium, X1, X2, X3, and X4 are independently selected from the group consisting of O, CH, and N, with the proviso that no more than two of combined O and N are selected, and Z is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, and halogen, any of which may be optionally substituted. Such compounds can increase glucose uptake by cells and preferably do not substantially increase adipogenesis.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: July 25, 2017
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Nikhil V. Dhurandhar, Bhaskar C. Das
  • Asymmetrical Si rhodamine and rhodol synthesis
    Patent number: 9714260
    Abstract: [Problem] To provide: a compound resulting from substituting with a silicon atom the oxygen atom at position 10 of a xanthene ring site of a rhodamine of which amino groups at position 3 and position 6 have an asymmetrical structure; a method for producing the compound; and a fluorescent probe that uses the compound. [Solution] The compound represented by general formula (I) or a salt thereof.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: July 25, 2017
    Assignee: THE UNIVERSITY OF TOKYO
    Inventors: Tetsuo Nagano, Kenjiro Hanaoka, Takahiro Egawa, Yu Kushida, Koji Numasawa, Takuya Myochin, Wen Piao
  • Ionic liquid supported organotin reagents for the manufacturing of radiopharmaceuticals compounds
    Patent number: 9714261
    Abstract: An ionic liquid supported organotin reagent of formula (I) A process for manufacturing the ionic liquid supported organotin reagent of formula (I), a process for manufacturing an halogenated or radio-halogenated compound using compound of formula (I), a device for implementing the halogenating process and a kit including the compound of formula (I) are also described.
    Type: Grant
    Filed: January 7, 2015
    Date of Patent: July 25, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE NANTES, UNIVERSITE D' ANGERS, UNIVERSITE DU MAINE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
    Inventors: Stephanie Legoupy, Djibril Faye, Jean-Francois Gestin, Holisoa Rajerison, Alain Faivre-Chauvet, Fabien Boeda
  • Composition for forming passivation layer, semiconductor substrate having passivation layer, method of producing semiconductor substrate having passivation layer, photovoltaic cell element, method of producing photovoltaic cell element and photovoltaic cell
    Patent number: 9714262
    Abstract: A composition for forming a passivation layer, comprising a compound represented by Formula (I): M(OR1)m. In Formula (I), M comprises at least one metal element selected from the group consisting of Nb, Ta, V, Y and Hf, each R1 independently represents an alkyl group having from 1 to 8 carbon atoms or an aryl group having from 6 to 14 carbon atoms, and m represents an integer from 1 to 5.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: July 25, 2017
    Assignee: Hitachi Chemical Company, Ltd.
    Inventors: Shuichiro Adachi, Masato Yoshida, Takeshi Nojiri, Yasushi Kurata, Tooru Tanaka, Akihiro Orita, Tsuyoshi Hayasaka, Takashi Hattori, Mieko Matsumura, Keiji Watanabe, Masatoshi Morishita, Hirotaka Hamamura
  • Selective hydrogenation of aldehydes with Ru/bidentate ligands complexes
    Patent number: 9714263
    Abstract: The present invention relates to processes for the reduction by hydrogenation, using molecular H2, of a C5-C20 substrate containing one or two aldehydes functional groups into the corresponding alcohols or diol, characterized in that said process is carried out in the presence of —at least one catalyst or pre-catalyst in the form of a ruthenium complex having a coordination sphere of the N1P3O2, wherein the coordinating atom N and one coordinating atom P are provided by a first bidentate ligand, and the two other coordinating atoms P2 are provided by a second bidentate ligand and the coordinating atoms O2 are provided by two non-linear carboxylate ligands; and —optionally of an acidic additive.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: July 25, 2017
    Assignee: Firmenich SA
    Inventors: Philippe Dupau, Lucia Bonomo, Laurent Kermorvan
  • Method for working up an aqueous lignin containing solution
    Patent number: 9714264
    Abstract: A method for working up an aqueous, alkaline-alcoholic and lignin containing solution via nanofiltration, wherein a permeate and a retentate are obtained, which permeate is an aqueous, lignin-starved solution and which retentate is an aqueous lignin-enriched solution.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: July 25, 2017
    Assignee: ANNIKKI GMBH
    Inventors: Anton Friedl, Abdel Halim Fuqaha, Felix Weinwurm, Thomas Ters
  • Mutagenic nucleoside analogs and uses thereof
    Patent number: 9714265
    Abstract: The present disclosure provides nucleoside analogs of Formula (I) or (II). The nucleoside analogs are expected to show multiple tautomerism and may increase the mutation of an RNA and/or DNA (be mutagenic) of a virus or cancer cell. The multiple tautomerism and mutagenesis of the nucleoside analogs may be adjusted by substituting the nucleoside analogs with one or more electron-donating groups and/or electron-withdrawing groups to increase or decrease the pKa (e.g., to a pKa between 5.5 or 8.5). The present disclosure also provides pharmaceutical compositions and kits including the nucleoside analogs and methods of treating a viral infection (e.g., influenza, HIV infection, or hepatitis) or cancer using the nucleoside analogs, pharmaceutical compositions, or kits.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: July 25, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: John M. Essigmann, Andrei Tokmakoff, Bogdan I. Fedeles, Vipender Singh, Chunte Peng
  • Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (AKR1C3)
    Patent number: 9714266
    Abstract: The invention relates to AKR1C3 inhibitors of formula (I) and to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of bleeding disorders and endometriosis.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: July 25, 2017
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich Bothe, Matthias Busemann, Naomi Barak, Andrea Rotgeri, Oliver Martin Fischer, Tobias Marquardt
  • Method for processing thin stillage and apparatus for producing a protein containing product
    Patent number: 9714267
    Abstract: A method for processing thin stillage (TS), characterized by the following steps: a) feeding of thin stillage (TS) into a working vessel (3); b) concentrating of thin stillage (TS) in a filtration unit (9); and c) returning of a first substream of concentrated thin stillage to the thin stillage (TSI) present in the working vessel (3) in order to adjust the solids content, and apparatus for producing a protein-containing product of value.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: July 25, 2017
    Assignee: GEA Mechanical Equipment GmbH
    Inventors: Mario Emanuele, Knud Schöneberg
  • Use of inhibitory peptides for the treatment of inflammatory diseases
    Patent number: 9714268
    Abstract: An isolated peptide is disclosed which comprises an amino acid sequence being at least 80% homologous to the sequence as set forth in SEQ ID NO: 1 (PERYQNLSPV), the isolated peptide comprising a nuclear targeting activity, the peptide being no longer than 20 amino acids.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: July 25, 2017
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Rony Seger, Eldar Zehorai
  • Inorganic-binding peptides and quality control methods using them
    Patent number: 9714269
    Abstract: The present invention relates to quality control methods using inorganic binding peptides, wherein inorganic entities are identified using inorganic-binding peptides specifically binding to the inorganic entity of interest. In particular, the invention includes a method for the identification of defects or inhomogeneities on a surface by detecting an inorganic entity of interest. It further includes a method for the isolation of powder particles comprising an inorganic entity of interest from a mixture of powder particles. In addition, the present invention relates to inorganic-binding peptides comprising the amino acid sequence MTWDPSLASPRS (SEQ ID NO: 31) and the amino acid sequence LNAAVPFTMAGS (SEQ ID NO: 32), respectively.
    Type: Grant
    Filed: July 6, 2009
    Date of Patent: July 25, 2017
    Assignees: UNIVERSITE DE LIEGE INTERFACE ENTERPRISES UNIVERSITE, ARCELORMITTAL INVESTIGACIÓN Y DESARROLLO, S.L., GESVAL S.A., SYMBIOSE BIOMATERIALS S.A.
    Inventors: Christelle Vreuls, Cécile Van De Weerdt, Catherine Archembeau, André Renard, Joseph Martial
  • a4B7 integrin thioether peptide antagonists
    Patent number: 9714270
    Abstract: The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of ?4?7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: July 25, 2017
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Brian Troy Frederick, Larry C. Mattheakis
  • Cyclosporine analogue molecules modified at amino acid 1 and 3
    Patent number: 9714271
    Abstract: Analogs of cyclosporin-A are disclosed comprising modifications of the substituents as the positions of amino acids 1 and 3, according to the following Formula. The disclosed compounds include compounds having affinity for cyclophilin, including cyclophilin-A, and reduced immunosuppressivity in comparison with cyclosporin-A and analogs thereof modified solely at position 1.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: July 25, 2017
    Assignee: ContraVir Pharmaceuticals, Inc.
    Inventors: Alexander Hegmans, Bruce W. Fenske, Dan J. Trepanier, Mark D. Abel, Daren R. Ure, Shin Sugiyama
  • Recombinant proteins of parapdxvirus ovis and pharmaceutical compositions therefrom
    Patent number: 9714272
    Abstract: The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and to fragments of said recombinant proteins, and to the use of said recombinant proteins or fragments for the preparation of pharmaceutical compositions.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: July 25, 2017
    Assignee: AICURIS GMBH & CO. KG
    Inventors: Olaf Weber, Sonja Maria Tennagels, Angela Siegling, Tobias Schlapp, Andrew Allan Mercer, Stephen Bruce Fleming, Hans-Dieter Volk
  • Expression systems and associated methods
    Patent number: 9714273
    Abstract: A method of producing synthetic spider silk, including: transforming Escherichia coli with an expression vector; fermenting the transformed E. coli in a culture medium; inducing spider silk protein expression in the cultured E. coli; extracting the spider silk; and purifying the spider silk. Related vectors and genetically modified cells are also disclosed.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: July 25, 2017
    Assignee: Utah State University
    Inventors: Randolph V. Lewis, Dong Chen, Justin A. Jones, Sreevidhya T. Krishnaji, Paula F. Oliveira, Gargi Bhattacharyya
  • Fusion proteins of superfolder green fluorescent protein and use thereof
    Patent number: 9714274
    Abstract: The present disclosure pertains to methods of producing recombinant peptides that contain between 10 and 200 amino acid residues using novel carrier proteins derived from superfolder green fluorescent protein and its mutants.
    Type: Grant
    Filed: March 25, 2013
    Date of Patent: July 25, 2017
    Assignee: Suzhou Kunpeng Biotech Co., Ltd.
    Inventors: Wenshe Liu, Wei Wan
  • Cancer antigen
    Patent number: 9714275
    Abstract: Cancer cells when treated with cisplatin, paclitaxel, gemcitabine, Mycobacterium w or combination there of shows altered protein profile. Thus altered protein profile has at least one protein commonly expressed or over expressed. The commonly expressed or over expressed protein induces immune response specific to cancer cells (homologue and hetrologus) of tissue/organ of origin. The immune response generated by administration of commonly expressed or over expressed antigen not reactive to normal cells and cancer cells or different tissue/organ of origin.
    Type: Grant
    Filed: July 4, 2012
    Date of Patent: July 25, 2017
    Assignee: Cadila Pharmaceuticals Ltd.
    Inventors: Indravadan Ambalal Modi, Rajiv Indravadan Modi, Bakulesh Mafatlal Khamar, Chandreshwar Prasad Shukla, Vipul Sitaram Thakkar, Nirav Manojkumar Desai
  • Growth differentiation factor 15 (GDF-15) polypeptides
    Patent number: 9714276
    Abstract: GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: July 25, 2017
    Assignee: Amgen Inc.
    Inventors: Yumei Xiong, Yi Zhang, Jackie Zeqi Sheng, Agnes Eva Hamburger, Murielle Veniant-Ellison, Grant Shimamoto, Xiaoshan Min, Zhulun Wang, Jie Tang, Gunasekaran Kannan, Kenneth W. Walker, Bryan Lemon
  • Pegylated glucagon and GLP-1 co-agonists for the treatment of obesity
    Patent number: 9714277
    Abstract: This disclosure provides pegylated GLP-1/glucagon agonist peptides for the treatment of metabolic diseases, e.g., obesity.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 25, 2017
    Assignee: MedImmune Limited
    Inventor: Maria Bednarek
  • Use of ICOS-based CARs to enhance antitumor activity and CAR persistence
    Patent number: 9714278
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a genetically modified Th17 cell to express a CAR having an antigen binding domain, a transmembrane domain, and an ICOS intracellular signaling domain.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: July 25, 2017
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Sonia Guedan Carrio, Yangbing Zhao, John Scholler
  • HIV vpr-specific T-cell receptors
    Patent number: 9714279
    Abstract: The instant invention provides TCRs having one or more amino acid substitutions that bind to the AL9 epitope of the HIV protein vpr (AIIRILQQQL).
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: July 25, 2017
    Assignee: Altor Bioscience Corporation
    Inventors: Marilyn Fernandez, Bai Liu, Warren D. Marcus, Hing C. Wong
  • HLA G-modified cells and methods
    Patent number: 9714280
    Abstract: Disclosed herein are genetically modified cells expressing HLA-G (e.g., cell surface HLA-G) persistently, and nucleic acid compositions useful for generating such genetically modified cells. Also disclosed are cell therapy methods that utilize genetically modified cells that express HLA-G persistently. The HLA-G genetic modifications described herein provide the cells with characteristics of reduced immunogenicity and/or improved immunosuppression, such that these cells have the promise of being universal or improved donor cells for transplants, cellular and tissue regeneration or reconstruction, and other therapies.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: July 25, 2017
    Assignee: ESCAPE THERAPEUTICS, INC.
    Inventor: Basil M. Hantash
  • Fibronectin based scaffold domain proteins that bind IL-23
    Patent number: 9714281
    Abstract: The present invention relates to fibronectin based scaffold domain protein that bind interleukin 23 (IL-23), specifically the p19 subunit of IL-23. The invention also relates to the use of the innovative proteins in therapeutic applications to treat autoimmune diseases. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: July 25, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ruchira Dasgupta, Alex Bush, Lumelle Schneeweis, Linda Engle
  • Optimized Fc variants and methods for their generation
    Patent number: 9714282
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: July 25, 2017
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa